RESTASIS MULTIDOSE Drug Patent Profile

Which patents cover Restasis Multidose, and what generic alternatives are available?

Restasis Multidose is a drug marketed by Abbvie and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-two patent family members in twenty-six countries.

The generic ingredient in RESTASIS MULTIDOSE is cyclosporine. There are eighteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Restasis Multidose

A generic version of RESTASIS MULTIDOSE was approved as cyclosporine by HIKMA on October 29^th, 1999.

Summary for RESTASIS MULTIDOSE

International Patents:	62
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	53
Patent Applications:	7,087
Drug Prices:	Drug price information for RESTASIS MULTIDOSE
What excipients (inactive ingredients) are in RESTASIS MULTIDOSE?	RESTASIS MULTIDOSE excipients list
DailyMed Link:	RESTASIS MULTIDOSE at DailyMed

See drug prices for RESTASIS MULTIDOSE

Recent Clinical Trials for RESTASIS MULTIDOSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southern College of Optometry	PHASE4
Mohsen Pourazizi	PHASE1
OphRx Ltd.	Early Phase 1

See all RESTASIS MULTIDOSE clinical trials

Pharmacology for RESTASIS MULTIDOSE

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for RESTASIS MULTIDOSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RESTASIS MULTIDOSE	Ophthalmic Emulsion	cyclosporine	0.05%	050790	1	2020-01-29
RESTASIS MULTIDOSE	Ophthalmic Emulsion	cyclosporine	0.05%	050790	1	2014-01-13

US Patents and Regulatory Information for RESTASIS MULTIDOSE

RESTASIS MULTIDOSE is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes	8,292,129		Y		Y
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes	8,561,859		Y		Y
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes	9,676,525		Y		Y
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016		RX	Yes	Yes	9,669,974		Y		Y

Expired US Patents for RESTASIS MULTIDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016	8,629,111
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016	8,685,930
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016	8,648,048
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016	8,633,162
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016	8,642,556
Abbvie	RESTASIS MULTIDOSE	cyclosporine	EMULSION;OPHTHALMIC	050790-002	Oct 27, 2016	9,248,191

International Patents for RESTASIS MULTIDOSE

See the table below for patents covering RESTASIS MULTIDOSE around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201603517	PROTECTIVE CAP FOR A DISPENSER, AND DISCHARGE DEVICE FOR DISCHARGING PHARMACEUTICAL AND/OR COSMETICAL LIQUIDS
Australia	2640995
Germany	3851152
European Patent Office	2210670	Dispositif de sortie (Discharge device)
European Patent Office	2210674
Slovenia	3083431
World Intellectual Property Organization (WIPO)	2005032577

Supplementary Protection Certificates for RESTASIS MULTIDOSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049079	LUC00006	Luxembourg		PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323

Market Dynamics and Financial Trajectory for RESTASIS MULTIDOSE: A Comprehensive Analysis

Last updated: December 28, 2025

Summary

RESTASIS MULTIDOSE (cyclosporine ophthalmic emulsion 0.05%) is a prominent pharmacological intervention primarily used for the treatment of dry eye disease associated with keratoconjunctivitis sicca. Its market landscape has seen notable shifts driven by patent expirations, competitive entries, and evolving ophthalmic treatment protocols. This analysis delineates the current market dynamics, evaluates the financial trajectory over the next five years, and discusses strategic implications for stakeholders.

---

What Is RESTASIS MULTIDOSE and How Has Its Market Evolved?

RESTASIS MULTIDOSE—developed under the brand name Restasis by Allergan (acquired by AbbVie in 2020)—was approved by the FDA in 2003. It revolutionized dry eye management by offering a sustained-release cyclosporine formulation promoting tear production. The multi-dose (MULTIDOSE) formulation replaced earlier vial-based versions, providing ease of administration and patient compliance.

Market Evolution Timeline	Year	Key Events	Impact
2003	FDA approval for Restasis (vial form)	Initiated dry eye treatment paradigm shift
2014	Patent expiration on key formulations	Entry of generics increased cost competition
2018	Launch of Cequa (cyclosporine ophthalmic solution 0.09%) by Sun Pharma	Heightened competition, expanded options
2019	Entry of Eysuvis (corticosteroid), indicating market diversification	Market broadening
2020	AbbVie acquires Allergan; patent litigations continue	Consolidation and strategic positioning
2021+	Rise of biosimilars and generics focus	Price erosion and access expansion

---

Current Market Dynamics

1. Market Size and Growth Trends

• Global Dry Eye Disease Market: Valued at USD 5.5 billion in 2022, with a CAGR of approximately 6% projected through 2030.[1]
• Restasis Market Share: Historically accounted for over 70% of prescription dry eye therapies in the U.S. pre-generic entry.[2]

2. Patent Status and Generic Competition

• Patent Expiry: The original patents on Restasis expired in 2021, opening the market to generics.
• Generics and Biosimilars: Multiple generic formulations were launched in 2021-2022, causing significant price declines.
• Market Response: Allergan/AbbVie responded with rebates and patient assistance programs to retain market share.

3. Competitive Landscape

Competitors	Product Name	Formulation	Differentiation	Market Position
Allergan/AbbVie	RESTASIS MULTIDOSE	Cyclosporine 0.05%	Original brand, proven efficacy	Market leader (historically)
Sun Pharma	Cequa	Cyclosporine 0.09%	Higher concentration, bioavailability	Rising competitor
Other Generics	Various	Cyclosporine solutions	Cost-effective alternative	Growing share
Corticosteroids	Eysuvis, Lotemax	Corticosteroids	Different mechanism, secondary option	Niche segments

4. Regulatory and Reimbursement Factors

• Reimbursement Challenges: Insurance plans often favor generics post-patent expiry.
• Pricing Dynamics: Original formulations commanded premiums (~USD 500-600/month); generics have driven prices below USD 300/month.
• FDA Regulations: New formulations require FDA approval, impacting market entry strategies.

5. Prescriber and Patient Acceptance

• Physician Confidence: Restasis’s long-standing efficacy sustains demand despite generics.
• Patient Preferences: Cost sensitivity influences prescription patterns; some favor lower-cost options.
• Adherence Factors: Multi-dose preservative-free formulations improve compliance.

---

Financial Trajectory Analysis (2023-2028)

1. Revenue Projections

Year	Estimated Global Revenue	Growth Rate	Key Assumptions
2023	USD 950 million	-15% decline post-generic entries	Reflects market saturation and increased competition
2024	USD 900 million	-5%	Stabilization with aggressive marketing
2025	USD 950 million	+5%	Introduction of new formulations or indications
2026	USD 1.0 billion	+5.2%	Market refocus and increased adoption for refractory cases
2027	USD 1.05 billion	+5%	Potential pipeline products impacting growth
2028	USD 1.1 billion	+4.8%	Market maturation, geopolitical factors considered

Note: The initial decline is driven by patent expiry effects, with subsequent recovery through innovation and market segmentation.

2. Cost Structure and Margins

Aspect	Estimated Figures	Notes
R&D Expenses	8-10% of revenues	Focus shifted to biosimilars and delivery systems
Manufacturing Costs	30-35% of revenues	Economies of scale with increased generics
Marketing & Promotion	15-20% of revenues	Direct-to-physician campaigns
Gross Margin	50-55% (post-generic competition)	Compression expected over time
Operating Margin	20-25%	Conservative estimate, subject to market conditions

3. Investment Incentives

• Pipeline Development: Focus on preservative-free, sustained-release, and combination therapies.
• Strategic Collaborations: Partnering with biosimilar manufacturers to reduce costs.
• Market Expansion: Targeting emerging markets and off-label indications.

---

Comparative Analysis: Restasis MULTIDOSE vs. Competitors and Alternatives

Parameter	Restasis MULTIDOSE	Cequa (Sun Pharma)	Generic Cyclosporine Solutions	Eysuvis (Steroid)
Composition	Cyclosporine 0.05%	Cyclosporine 0.09%	Cyclosporine solutions	Loteprednol (corticosteroid)
FDA Approval Year	2003	2018	2021	2020
Cost (USD/month)	USD 500-600 (brand)	USD 300-400	USD 100-250	USD 500+ (steroid)
Efficacy	Established	Slightly higher concentration, comparable	Similar efficacy, variable formulations	Different mechanism, short-term use
Reimbursement	Generally favorable	Similar, with some restrictions	Widely reimbursed in markets	Restricted to specific indications
Market Share	~70% (pre-generic era)	Growing rapidly	Increasing	Niche, acute treatment

---

Regulatory and Policy Landscape

• FDA: Strict guidelines on ophthalmic drug approvals, bioequivalence standards, and patent litigation.
• EMA and International Markets: Varying approval timelines; patent laws influence availability.
• Reimbursement Policies: CMS and private insurers' coverage policies favor generics, pressuring brand revenue.

---

Strategic Implications for Stakeholders

Stakeholder	Opportunities	Risks
Pharmaceutical Companies	Innovation in drug delivery (e.g., sustained-release), pipeline expansion	Patent cliff leading to revenue decline
Investors	Growth in biosimilars and emerging markets post-patent expiry	Market saturation, pricing pressures
Healthcare Providers	Adoption of cost-effective alternatives, combination therapies	Prescriptive inertia favoring established brands
Payers	Cost containment via generics and biosimilars	Reduced margins for innovator companies

---

Conclusion

RESTASIS MULTIDOSE continues to demonstrate resilience despite patent expirations and increasing competition. The initial decline in revenues post-generic entry is expected to stabilize, supported by ongoing innovation, pipeline development, and market segmentation. The growth prospects hinge on strategic adaptation within a highly competitive and regulated environment.

---

Key Takeaways

• The post-patent landscape has intensified price competition, compelling companies to innovate.
• Biosimilar and generic formulations dominate share, pressuring original brand profitability.
• Market expansion into emerging regions offers growth potential; however, regulatory hurdles persist.
• Investment in formulation improvements and combination therapies can rejuvenate revenue streams.
• Stakeholders must navigate reimbursement landscapes thoughtfully, balancing innovation and cost-effectiveness.

---

FAQs

1. How has patent expiry impacted RESTASIS MULTIDOSE’s market share?

Patent expiry in 2021 led to the entry of multiple generics, causing significant erosion of market share and price reductions. However, brand loyalty and prescriber confidence have mitigated some declines.

2. What are the main competitors to RESTASIS MULTIDOSE?

Major competitors include Cequa (Sun Pharma), generic cyclosporine formulations, and emerging steroid-based therapies like Eysuvis.

3. What strategies can restore or improve RESTASIS MULTIDOSE’s market position?

Innovations such as sustained-release formulations, new indications, better patient adherence solutions, and strategic partnerships can bolster market presence.

4. What is the outlook for dry eye disease treatment markets?

The market is projected to grow at a CAGR of about 6% until 2030, driven by aging populations, increased awareness, and technological advancements.

5. How do policy and reimbursement influence the future of RESTASIS MULTIDOSE?

Policies favoring cost-effective generics accelerate market penetration but challenge brand retention. Conversely, reimbursement strategies that favor innovation can support sustainable revenues.

---

References

1. MarketResearch.com. "Global Dry Eye Disease Market Report," 2022.
2. IQVIA. "U.S. Prescription Data for Dry Eye Therapeutics," 2022.